Financing French Biotech and Medtech

### 1st Semester 2017

- **492 M€ raised by French biotech and medtech**
  - **€137 M** in private equity
  - **€82 M** in IPO
  - **€273 M** post-IPO

### Private Equity

#### Global pharma & biotech investment activity

- **2016**: €5.69 Bn, 504 deals
- **1st semester 2017**: €3.32 Bn, 259 deals

### French biotech and medtech

- **€137 M** in private equity
- **19 companies funded**
- **€7.2 M** funding on average
- Biotech is the largest segment (80% of amounts)
- Largest funding round made by Vivet Therapeutics: €37.5 M

### Initial Public Offerings

- **Feb 2017**: **Inventiva** (€48 M)
- **Feb 2017**: **Lysogene** (€22.6 M)
- **May 2017**: **Valbiotic** (€11.5 M)

### Post-IPO funding

- **€273 M** post-IPO
- **23 companies funded**
- **€11.8 M** funding on average
- Largest funding round made by Erytech Pharma: €70.5 M

### Top 10 listed French biotech and medtech

- **Orpegen**: €2,900 M
- **Genfit**: €600 M
- **Inventiva**: €500 M
- **Lysogene**: €377 M
- **Novoceastra**: €320 M
- **Nices**: €210 M
- **Erytech**: €175 M
- **Valneva**: €170 M
- **Transgene**: €140 M
- **Meditech**: €120 M

### Sources

- BioCentury (July 2017), KPMG (2017), France Biotech